Previous Next

Register now


To stay up-to-date with the latest updates about the Biosimilar Week and activities under the Biosimilar Education Grant register here

About Biosimilar Week


Supporting the future of sustainable healthcare through the appropriate use of biosimilar medicines


Biosimilar Week is an integral component of a comprehensive 3-year education program focusing on the appropriate use of biosimilar medicines, developed collaboratively by experts across medical specialities, government and the medicines industry. The Program is coordinated by GBMA Education and funded by the Australian Government through the Biosimilar Educational Grant, announced in April 2018.


Biosimilar Week will commence with an official announcement from the Hon Greg Hunt, Minister of Health, highlighting the critical role that biosimilar medicines play in the future of a sustainable healthcare system in Australia.

Biosimilar Medicines

Did you know...

Biological medicines are pharmaceutical products that contain one or more active substances derived from living cells or organisms1. A biosimilar medicine is a highly similar version of an already registered biological medicine (the reference biological medicine)1. The regulatory conditions required for biosimilar medicines in Australia mean that a biosimilar medicine approved for use in the Australian market can be said to have no clinically meaningful difference and be therapeutically equivalent to its reference biological medicine1,2.

References:
  1. Australian Government – Department of Health. Biosimilar medicines: the basics for health care professionals. P11756. Updated: March 2017. Available at: http://www.health.gov.au/internet/main/publishing.nsf/content/biosimilar -awareness-initiative/$File/Biosimilar-medicines-the-basics-for-healthcare-professionals-brochure.pdf. Accessed 27 August 2018
  2. Therapeutic Goods Administration. Biosimilar medicines regulation, Version 2.2. Accessed from: https://www.tga.gov.au/publication/biosimilar-medicines-regulation. Updated: April 2018. Accessed on: 27 August 2018.
References:
  1. Aust Govt DoH. Biosimilar medicines: the basics for health care professionals. P11756. Updated: March 2017. Available at: http://www.health.gov.au/internet/main/publishing.nsf/content/biosimilar-awareness-initiative/$File/Biosimilar-medicines-the-basics-for-healthcare-professionals-brochure.pdf. Accessed 27 August 2018.
  2. Dörner T, et al. Ann Rheum Dis 2016; 75(6): 974–82.
  3. Schneider CK, et al. Ann Rheum Dis 2013; 72(3): 315–18.
  4. Schiestl M, et al. Drug Design, Dev Ther 2017; 11: 1509–15.
  5. Van den Hoven A. Biosimilar medicines clinical use: an experience based-EU perspective. Available at https://www.medicinesforeurope.com/docs/20170713%20-%20Biosimilar%20Medicines%20Group,%20EU%20experience-AVH-US%20FDA%20Adcom.pdf. Accessed February 2019.
  6. IMS Institute for Healthcare Informatics. Delivering on the Potential of Biosimilar Medicines. 2016. Available at https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/delivering-on-the-potential-of-biosimilar-medicines.pdf. Accessed February 2019.
  7. Aust Govt DoH. How have biosimilars been used around the world? Updated 7 December 2016. Available at http://www.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-hp-how-biosimilar-medicines-used-around-the-world. Accessed February 2019.
  8. Cohen HP, et al. Drugs 2018; 78(4): 463–78.
  9. Aust Govt DoH. Biosimilar Uptake Drivers. Available at http://www.pbs.gov.au/info/general/biosimilars. Accessed 1 October 2018.
  10. Aust Govt DoH. Implementation Framework: Biosimilars Awareness Initiative V2. November 2015.
  11. Aust Govt DoH. Why are biosimilar medicines important? Updated 23 March 2017. Available at http://www.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-why-are-biosimilar-medicines-important. Accessed 1 October 2018.
  12. Gleeson D, et al. Aust Health Rev 2017; Nov 9. doi: 10.1071/AH17031. [Epub ahead of print].

Biosimilar Events in 2019


Time Event
March 7-10 APP 2019 conference
  1. Biosimilar update with Associate Professor Michael Ward Saturday 9th March: 2:30-3:00pm; Arena 1A
  2. Meet Associate Professor Michael Ward GBMA Education Stand No. 28 & 29
    Friday 8th March: 12:30-2:30pm | 3:30-4:30pm
    Saturday 9th March: 3:30-4:30pm
  3. Register for Biosimilar Week GBMA Education Stand No. 28 & 29
April 29 - May 3 Biosimilar Week
  1. Launch Biosimilar Week
  2. Video release of insights from healthcare professionals across various specialties and hospital pharmacy
  3. Launch of the Biosimilar Education Hub
    • Quarterly literature updates on biosimilar medicines
    • Speciality group and pharmacist focussed information
    • Interactive content
August - September National Multidisciplinary Event
This event will be an opportunity for healthcare professionals across various specialties to share the latest updates and insights on Biosimilar Medicine
September - Ongoing Hospital-based education sessions
State based hospital education sessions at various teaching hospitals nationwide
July - November Conference attendance and education sessions
GBMA Education will continue their presence at various education sessions and conferences throughout 2019 spanning the various pharmacy, GP and specialty areas

These are the confirmed events for the remainder of 2019, GBMA Education will communicate more broadly on the specific activities as we move throughout the year.

Quarterly literature reviews


The quarterly literature reviews provide an update to the comprehensive literature search previously conducted on behalf of the Department of Health. To inform the activities related to GBMA Education’s Biosimilar Education Grant these reviews examine all international and Australian clinical, academic and policy journals in relation to biosimilar medicines.

The reviews are conducted with an emphasis on ensuring that the evidence is up-to-date in the following key topic areas:

  • Comparability of biosimilar medicines to reference biological medicine, specifically in reference to substitution (including single switch and multiple switch scenarios), and extrapolation of indication
  • Biosimilar medicine uptake related to prescribing and dispensing trends, particularly evidence relating to policies on biosimilar medicine use
  • Health outcomes and adverse events of biological and biosimilar medicines from a pharmacovigilance perspective
  • Current perceptions of biosimilar medicines (qualitative and quantitative evidence) relating to awareness, confidence, attitudes and acceptance